Tandem Investment Advisors Inc. Reduces Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Tandem Investment Advisors Inc. lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,177 shares of the company’s stock after selling 3,466 shares during the quarter. Tandem Investment Advisors Inc.’s holdings in Henry Schein were worth $4,102,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. raised its position in shares of Henry Schein by 2.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock valued at $459,000 after buying an additional 122 shares during the last quarter. Aurora Investment Counsel raised its position in shares of Henry Schein by 0.7% during the third quarter. Aurora Investment Counsel now owns 20,641 shares of the company’s stock valued at $1,533,000 after buying an additional 140 shares during the last quarter. Arizona State Retirement System raised its position in shares of Henry Schein by 0.4% during the fourth quarter. Arizona State Retirement System now owns 35,890 shares of the company’s stock valued at $2,717,000 after buying an additional 149 shares during the last quarter. Studio Investment Management LLC raised its position in shares of Henry Schein by 3.9% during the fourth quarter. Studio Investment Management LLC now owns 4,160 shares of the company’s stock valued at $332,000 after buying an additional 155 shares during the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Henry Schein by 3.4% during the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company’s stock valued at $321,000 after buying an additional 161 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Activity

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on HSIC. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, March 6th. SVB Leerink assumed coverage on shares of Henry Schein in a research report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price target on the stock. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. Evercore ISI boosted their price target on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research report on Wednesday, February 28th. Finally, Leerink Partnrs restated a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $81.09.

Henry Schein Trading Down 1.4 %

HSIC stock traded down $1.02 during mid-day trading on Wednesday, reaching $70.20. 1,067,027 shares of the stock traded hands, compared to its average volume of 1,112,613. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $85.39. The stock has a market capitalization of $9.02 billion, a PE ratio of 22.29, a PEG ratio of 1.75 and a beta of 0.87. The business has a 50-day moving average price of $74.63 and a two-hundred day moving average price of $72.52.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). The firm had revenue of $3.02 billion for the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company’s revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 EPS. Equities research analysts expect that Henry Schein, Inc. will post 5.07 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.